ZLDPF:OTC-Zealand Pharma A/S (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 100.09

Change

0.00 (0.00)%

Market Cap

USD 8.01B

Volume

198.00

Analyst Target

USD 36.83
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
ARGNF argenx SE

N/A

USD 36.93B
UCBJY UCB SA ADR

-1.04 (-1.04%)

USD 36.22B
UCBJF UCB SA

+0.01 (+0.00%)

USD 36.22B
GNMSF Genmab A/S

-5.00 (-2.35%)

USD 13.91B
WXIBF WuXi Biologics

N/A

USD 10.26B
WXXWY WuXi Biologics (Cayman) Inc

+0.04 (+0.81%)

USD 9.12B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 8.24B
IVBIY IVBIY

N/A

USD 7.83B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 7.73B
AKESF Akeso, Inc.

N/A

USD 7.54B

ETFs Containing ZLDPF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 79.86% 84% B 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 79.86% 84% B 89% A-
Trailing 12 Months  
Capital Gain 81.32% 84% B 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 81.32% 84% B 89% A-
Trailing 5 Years  
Capital Gain 199.40% 93% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 199.40% 92% A 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 60.31% 70% C- 78% C+
Dividend Return 60.31% 70% C- 77% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 97.23% 49% F 35% F
Risk Adjusted Return 62.02% 97% N/A 90% A-
Market Capitalization 8.01B 97% N/A 89% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector